[1] Hopkin J. Mechanisms of asthma[J]. Medicine, 2003,31(12):41-44.
[2] Fang C, Corrigan CJ, Ying S.The treatment targets of asthma: from laboratory to clinic[J]. Allergy Drug Targets, 2008,7(2):119-128.
[3] Walsh GM. Advances in the immunobiology of eosinophils and their role in disease[J]. Crit Rev Clin Lab Sci, 1999,36(5):453-496.
[4] Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hypersonsiveness and the late asthmatic response[J]. Lancet, 2000,356(9248):2144-2148.
[5] Haldar P, Brightling CE, Hargadon B,et al.Mepolizumab and exacerbations of refractory eosinophilic asthma[J]. 2009,360(10):973-984.
[6] Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia[J]. N Engl J Med, 360(10):985-993.
[7] Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study[J]. Am J Respir Crit Care Med, 2003,167(12):1655-1659.
[8] Walsh GM.Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions[J]. Curr Opin Mol Ther, 2009,11(3):329-336.
[9] Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma[J]. Am J Respir Crit Care Med, 2008,178(10):1002-1008.
[10]Deshpande DA,Dogan S,Walseth TF, et al. Modulation of calcium signaling by interleukin-13 in human airway smooth muscle: role of CD38/cyclic adenosine diphosphate ribose pathway[J]. Am J Respir Cell Mol Biol, 2004,31(1):36-42.
[11]Chiba Y,Nakazawa S, Todoroki M, et al. Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein[J]. Am J Respir Cell Mol Biol, 2009,40(2):159-167.
[12]Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A Phase I/II randomized, placebo-controlled trial[J]. Am J Respir Crit Care Med, 1999,160(6):1816-1823.
[13]Ma Y, Hayglass KT, Becker AB, et al.Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice[J]. Allergy, 2007,62(6):675-682.
[14]Bree A, Schlerman FJ, Wadanoli M, et al. IL-13 blockade reduces lung infammation after Ascaris suum challenge in cynomolgus monkeys[J]. J Allergy Clin Immunol, 2007,119(5):1251-1257.
[15]Blanchard C, Mishra A, Saito-Akei H, et al. Inhibition of human interleukin-13-induced respiratory and oesophageal in?ammation by anti-human-interleukin-13 antibody (CAT-354)[J]. Clin Exp Allergy, 2005,35(8):1096-1103.
[16]Availableat:http://www.cambridgeantibody.com/data/assets/pdfle/11030/CAT-354Mar07.pdf. Accessed January, 11,2008.
[17]Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies[J]. Lancet, 2007,370 (9596):1422-1431.
[18]Shimbara A, Christodoulopoulos P, Soussi-Gounni A, et al. IL-9 and its receptor in allergic and nonallergic lung disease: Increased expression in asthma[J]. J Allergy Clin Immunol, 2000,105(1Pt1):108-115.
[19]Cheng G, Arima M, Honda K, et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model[J]. Am J Respir Crit Care Med, 2002,166(3):409-416.
[20]White B, Leon F, White W, et al. Clinical therapeutics two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers[J]. Clin Ther, 2009,31(4):728-740.
[21]Hurst SD, Muchamuel T, Gorman DM, et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25[J]. J Immunol, 2002,169(1):443-453.
[22]Kim MR, Manoukian R, Yeh R, et al.Transgenic overexpression of human IL-17E results in eosinophilia,B-lymphocyte hyperplasia,and altered antibody production[J]. Blood, 2002,100(7):2330-2340.
[23]Berry M, Brightling C, Pavord I, et al. TNF-alpha in asthma[J].Curr Opin Pharmacol, 2007,7(3):279-282.
[24]Morjaria JB, Chauhan AJ, Babu KS, et al.The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial[J]. Thorax, 2008,63(7):584-591.
[25]Erin EM,Leaker BR,Nicholson GC,et al.The effects of a monoclonal antibody directed against tumor necrosisfactor-alpha in asthma[J]. Am J Respir Crit Care Med, 2006,174(7):753-762.
[26]Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma[J]. J Allergy Clin Immunol, 2008,121(1):5-10.
[27]Rabinowitz MH, Andrews RC, Becherer JD, et al.Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)[J]. J Med Chem, 2001,44(24):4252-4267.
[28]Walsh GM. Targeting airway infammation: novel therapies for the treatment of asthma[J]. Current Medicinal Chemistry, 2006,13(25):3105-3111.
[29]Wegmann M, Gøggel R, Sel S, et al. Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma[J]. Am J Respir Cell Mol Biol, 2007,36(1):61-67.
[30]Suzuki K, Morokata T, Morihira K, et al. In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031[J]. Biochem Biophys Res Commun, 2006,339(4):1217-1223.
[31]Morokata T, Suzuki K, Masunaga Y, et al. A novel, selective, and orally available antagonist for CC chemokine receptor 3[J]. J Pharmacol Exp Ther, 2006,317(1):244-250.
[32]Fryer AD, Stein LH, Nie Z, et al. Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction[J]. J Clin Invest, 2006,116(1):228-236.
[33]Kline JN, Krieg AM. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy[J]. Drug News Perspect, 2008,21(8):434-439.
[34]Vollmer J, Krieg AM.Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists[J]. Adv Drug Deliv Rev, 2009,61(3):195-204. |
